BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tonmya (cyclobenzaprine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tonmya (cyclobenzaprine)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06636786-867@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tonmya (cyclobenzaprine): Phase 2 readout est. (NCT06636786)
DESCRIPTION:Tonmya (cyclobenzaprine)\, phase 2.\nStudy: Prevention/Reductio
 n of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobe
 nzaprine HCl (TNX-102 SL)\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cyclobenzaprine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06636786
URL:https://assetmemo.bio/drug/cyclobenzaprine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621237-867@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Tonmya (cyclobenzaprine): Phase 2 readout est. (NCT07621237)
DESCRIPTION:Tonmya (cyclobenzaprine)\, phase 2\, Major Depressive Disorder.
 \nStudy: A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Part
 icipants With Major Depressive Disorder (MDD)\nEstimated primary completio
 n: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cyc
 lobenzaprine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07621237
URL:https://assetmemo.bio/drug/cyclobenzaprine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
